Introduction
Lymphatic vessels are highly prevalent in most tissues throughout the body and play a major role in regulating interstitial fluid balance, immune cell trafficking, and dietary fat absorption (1) . Within the intestinal tract, each intestinal villus contains a lymphatic lacteal that efficiently absorbs lipids that have been packaged as chylomicrons by enterocytes (2) (3) (4) . These intestinal lacteals then drain the lipid-rich chyle fluid to submucosal collecting lymphatic vessels for systemic fat absorption. The critical importance of lymphatic vessels in intestinal biology was recently demonstrated by diphtheria toxin-mediated ablation of lymphatic vessel endothelial hyaluronan receptor 1-expressing (LYVE1-expressing) lymphatic endothelial cells (LECs) in the adult mouse intestine, leading to sepsis-related lethality due to failed immune cell trafficking and breakdown of the intestinal barrier to gut microbiota (5) . In addition, a few recent studies have shown that lymphatic growth factors, such as intestinal VEGF-D and smooth muscle-derived VEGF-C, govern lacteal maintenance and dietary lipid absorption and that lacteals are continuously regenerating via VEGFR2-and VEGFR3-induced delta-like 4 (DLL4) signaling (6, 7) .
Despite the importance of the intestinal lymphatic system in immune surveillance and maintaining the intestinal barrier against microbes, the pathological versus protective roles of lymphatics in inflammatory bowel diseases (IBDs) still remain vastly elusive (8) . IBD encompasses both ulcerative colitis, which affects the colon, and Crohn's disease (CD), which primarily affects the distal ileum. Obstructed intestinal lymphatics are an established histological hallmark of CD, which stands somewhat in contrast to the lymphatic expansion observed in the mucosa of patients with IBDs (9-13), because it remains unclear whether lymphatic insufficiency due to obstruction is the cause of IBD or whether excessive lymphatic growth results from lymphatic insufficiency. In postoperative CD patients, a low density of lymphatic vessels has been attributed to recurrence of the disease (14) , and an inability of lymphatic vessels to function has been associated with lymphedema of the intestinal walls in IBD patients (15) . In animal models, VEGF-C administration was shown to stimulate lymphatic function and abrogate experimental colitis (16, 17) . Counterintuitively, it was also demonstrated by this same group that increases in VEGF-C-induced lymphangiogenesis Lymphatics play a critical role in maintaining gastrointestinal homeostasis and in the absorption of dietary lipids, yet their roles in intestinal inflammation remain elusive. Given the increasing prevalence of inflammatory bowel disease, we investigated whether lymphatic vessels contribute to, or may be causative of, disease progression. We generated a mouse model with temporal and spatial deletion of the key lymphangiogenic receptor for the adrenomedullin peptide, calcitonin receptor-like receptor (Calcrl), and found that the loss of lymphatic Calcrl was sufficient to induce intestinal lymphangiectasia, characterized by dilated lacteals and protein-losing enteropathy. /Prox1-CreER T2 mice exhibited exacerbated hallmarks of disease progression, and the lacteals demonstrated an inability to absorb lipids. Furthermore, we identified Calcrl/adrenomedullin signaling as an essential upstream regulator of the Notch pathway, previously shown to be critical for intestinal lacteal maintenance and junctional integrity. In conclusion, lymphatic insufficiency and lymphangiectasia caused by loss of lymphatic Calcrl exacerbates intestinal recovery following mucosal injury and underscores the importance of lymphatic function in promoting recovery from intestinal inflammation.
did not promote disease resolution in mice with acute experimental colitis (18) . Collectively, these results suggest either that lymphatic insufficiency may be causative of IBDs or that incorrect lymphatic expansion and function can exacerbate the disease phenotype. Although there are some large animal models, including several inbred strains of dogs, that exhibit intestinal lymphatic insufficiency, development of genetically tractable animal model systems in which the causes and consequences of lymphatic insufficiency can be addressed in the context of inflammation initiation and progression is needed (3, 19) .
Adrenomedullin (AM) is a small multifunctional peptide that signals through a heterodimer of a GPCR, calcitonin receptor-like receptor (gene = CALCRL, protein = CLR), and receptor activity-modifying protein 2 (RAMP2). These signaling partners are crucial for embryonic development since genetic deletion of Calcrl, Adm, or Ramp2 causes midgestation lethality due to arrested lymphangiogenesis in mice (20) (21) (22) . In adult mice, the inducible, global genetic deletion of the Calcrl gene causes systemic lymphatic insufficiency in a multitude of lymphatic vascular beds, leading to corneal edema, distal limb edema, and lymphangiectasia (23) . Since CLR is expressed in many cell types and tissues, we developed a genetic mouse model with inducible deletion of the Calcrl gene in lymphatic endothelium. Consistently, we found that loss of lymphatic Calcrl is sufficient to induce systemic lymphatic insufficiency and intestinal lymphangiectasia. Therefore, in this present study, challenging these mice with acute inflammation, we demonstrate that lymphatic CLR is not only important in maintaining functional intestinal lymphatic vessels but also critical in the pathophysiology of small intestinal inflammation, disease progression, and recovery.
Results
Lymphatic deletion of Calcrl is sufficient to induce small intestinal lymphangiectasia. Global deletion of the gene coding for the AM receptor, Calcrl, has been shown to induce multiorgan lymphangiectasia, resulting from dilated lymphatic vessels across several vascular beds (23) . Since Calcrl is commonly expressed in several cell types, including cells outside the vasculature, to distinguish the role of Calcrl in lymphatic cells compared with its role in other cell types in contributing to lymphangiectasia, we deleted Calcrl from the adult mouse lymphatic endothelium. We crossed Calcrl fl/fl mice to the previously described Prox1-CreER T2 line (24) . Five consecutive tamoxifen (TAM) injections (Supplemental Figure 1A ; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.92465DS1) in sex-and age-matched mice resulted in Calcrl deletion, as detected by an excision band by PCR (Supplemental Figure 1B) Figure 1A ). In the normal adult mouse intestinal tract, PROX1 has been shown to be expressed either in a subset of mature enteroendocrine cells or Ngn3 + enteroendocrine cells going through terminal differentiation or in their long-lived enteroendocrine progenitors (25, 26) . Therefore, to confirm the cell-specific expression of Prox1-CreER T2 , RiboTag technology was applied (27) Figure 1C , arrows) and few enteroendocrine cells (Supplemental Figure 1C, arrowheads) . Collectively, in the absence of a reliable CLR antibody, these data demonstrate a robust and specific loss of Calcrl in intestinal lymphatics using the RiboTag technology (27) .
Significant changes in body weight were observed in Calcrl fl/fl /Prox1-CreER T2 mice within 48 hours after the TAM injections as compared with control animals ( Figure 1C Figure 2 , B-F). Taken together, these results indicate that, under the conditions of Calcrl-mediated lymphatic insufficiency, mice exhibited prolonged survival and overall systemic health in the absence of any injury or challenge. In addition, the lack of any obvious liver pathology supports the interpretation that the protein-losing enteropathy phenotype (Figure 1D) is primarily a result of intestinal insufficiency. Therefore, these TAM-injected Calcrl (28) . In addition, we have previously shown that AM signaling through the CLR/RAMP2 receptor complex can dampen systemic inflammatory responses (21) . Since loss of lymphatic CLR gives rise to intestinal lymphangiectasia ( Figures 1 and 2 ), we wanted to use this model to determine the extent to which lymphatic vessels contribute to pathophysiological disease progression and recovery after injury and evaluate the antiinflammatory properties AM/CLR signaling in vivo. After receiving TAM injections, both Calcrl fl/fl and Calcrl fl/fl / Prox1-CreER T2 mice were challenged with indomethacin (INDO) -an established method to induce severe enteropathy in animals that recapitulates human CD by increasing mucosal permeability causing inflammation of the small intestine (29, 30) . Mice were evaluated either 1 day after INDO, to study the acute degree of injury, or after 7 days to assess disease resolution (Supplemental Figure 3A) .
Compared with Calcrl fl/fl controls, the small intestines of the Calcrl fl/fl /Prox1-CreER T2 animals were congealed and difficult to dissect. Macroscopic evaluation revealed visible, hemorrhagic lesions that persisted 7 days after INDO ( Figure 3A , bottom inset). One day after INDO in both the control and Calcrl fl/fl /Prox1-CreER T2 animals, histological examination of the intestines showed classical hallmarks of acute intestinal inflammation (31), including villous blunting, elongation of crypts, infiltration of inflammatory cells in the mucosa and submucosa, and thickening of the submucosa ( Figure 3B ). Importantly, the histological signs of inflammation markedly resolved in Calcrl fl/fl animals but persisted Figure 5D ). These data illustrate that expression of CLR in lymphatics is essential for promoting lipid absorption within intestinal lacteals.
Numerous in vitro and in vivo studies have characterized a robust function for AM and CLR signaling in the regulation of endothelial permeability by reorganization of both the tight junction protein zonula occludens-1 (ZO-1) and adherens junction protein VE-Cadherin (23, 33, 34) . Therefore, we sought to determine whether disruption of lymphatic lacteal junctional proteins in Calcrl fl/fl /Prox1-CreER T2 animals could be associated with the failure of appropriate lipid absorption. Indeed, lacteals of Calcrl fl/fl /Prox1-CreER T2 animals displayed more continuous VE-Cadherin staining compared with controls, with no consistent change in cell shape or morphology ( Figure 5E and Supplemental Figure  5A ). These findings were further recapitulated in an in vitro system, whereby knockdown of CALCRL in human LECs resulted in more linearized localization of both VE-Cadherin and ZO-1 at cell-cell junctions, compared with the jagged cell-cell junctions exhibited in control siRNA-treated cells (Figure /Prox1-CreER T2 mice after TAM treatment, 1 day after INDO challenge, and 7 days after INDO challenge. n = 5-10 mice per group. Quantitative data are represented as a box-and-whisker plot, with bounds from 25th to 75th percentile, median line, and whiskers ranging from minimum to maximum inflammation scores. Significance was determined by 2-way ANOVA, *P < 0.05. 5F). These results emphasize the influence of CLR signaling in intestinal lymphatic endothelial junctions and lipid uptake, which are independent of the ability of enterocytes to absorb lipids.
Notch signaling is downregulated in Calcrl-deficient LECs. Notch signaling has very recently been identified as an important mediator of intestinal inflammation and lacteal maintenance. Notch ligands DLL1 and DLL4 are expressed in intestinal crypts and are upregulated during inflammation (35) , and continuous lymphatic-specific Dll4 expression induced by VEGFR2 and VEGFR3 is important in the regeneration and proper functioning of lacteals (6) . Interestingly, in arterial endothelial cells, AM treatment robustly upregulates numerous Notch pathway components under conditions of hypoxia and regulates Notch pathway components in vascular progenitors during arterial differentiation (36, 37) .
Therefore, consistent with these findings, we observed a pronounced increase in DLL4 in the crypts and whole intestine ( Figure 6A , arrowheads, and Supplemental Figure 5B ) -likely representative of the critical role Notch plays in intestinal stem cell proliferation and regeneration -while the Calcrl fl/fl /Prox1-CreER T2 lacteals had little to no DLL4 expression compared with control animals ( Figure 6A, arrows and boxes) . In addition, siRNA-mediated knockdown of CALCRL in human LECs showed downregulation of several Notch pathway components, along with downregulation of activated NOTCH1 and DLL4 by immunostaining ( Figure 6, B-D) . Conversely, treating human LECs with human AM peptide increased the expression of Notch components (Figure 6 , E-G). Collectively, these data provide a critical cross-link between a robust lymphangiogenic signaling cue and its downstream effector pathway, both of which are essential for mediating intestinal lacteal integrity, function, and regeneration during intestinal inflammation. 
Discussion
There exists substantial controversy about whether lymphatic expansion during conditions of IBD occurs as an adaptive or aggravating response (3) . The answer to this question is likely very complex and largely dependent on the stage of disease progression. For example, the expansion of lymphatics in discrete areas of the gut that are not histologically affected by inflammation suggests that lymphatic vessels probably play an adaptive role during acute, subclinical phases of IBD (10) . Moreover, the persistence of lymphangiectasia (but not blood vascular density) following intestinal recovery also suggests that lymphatics may play a protective role during the recovery phases of IBD by limiting inflammation (38) . In contrast, rat and pig surgical models of lymphatic obstruction revealed marked regional enteritis and colitis with edema, . Quantitative data are represented as box-and-whisker plots, with bounds from 25th to 75th percentile, median line, and whiskers ranging from minimum to maximum normalized fold change over Calcrl fl/fl from 4 independent studies. GAPDH, RN18S, and ACTB were used as housekeeping controls. Significance was determined by Student's t test(tail = 2, type = 2), *P < 0.05. (C, D, F , and G) DLL4-stained (C and F) and activated NOTCH1-stained (D and G) human neonatal dermal lymphatic endothelial cells after control siRNA or CALCRL siRNA treated with vehicle (C and D) or 10 nM AM treatment (F and G). Images are representative of 3 independent knockdown experiments and treatment studies. Scale bar: 100 μm.
tissue remodeling, and increased inflammatory cytokines (39, 40) , all of which clearly demonstrate that alterations in normal lymphatic function can be causative of IBD. Taken together, these studies support the concept that lymphangiectasia during early and recovery phases of IBD may be beneficial and that disturbances or stasis of lymphatic function during chronic IBD can exacerbate the condition and lead to an aggravated clinical presentation. Therefore, the genetic mouse model of lymphatic insufficiency presented herein provides us with an opportunity to further elucidate the functions of lymphatic vessels and AM signaling in mucosal injury and inflammation from several distinct perspectives.
Recently, using lymphatic-specific Dll4-null mice, it was shown that lymphatic DLL4 is essential for migration, lacteal tip cell survival, fat absorption, and regeneration of intestinal lacteals (6) . Blocking DLL4 function using antibodies downregulates the Notch1-Dll4 axis and leads to dilation of collecting lymphatic vessels and impaired wound healing in adult mouse skin (41) . In this study, we identify lymphatic Calcrl as an upstream regulatory factor that governs DLL4 expression to influence the resolution of inflammation after drug-induced acute intestinal injury. AM/CLR signaling has been shown to exert upstream regulation of the Notch pathway in the blood endothelium of zebrafish, and our current study substantiates the relevance of this pathway to the mammalian lymphatic vascular system in a disease model (41, 42) . The lymphatic deletion of Calcrl caused dilated lacteals and protein-losing enteropathy that are characteristic of clinical intestinal lymphangiectasia. Moreover, lacteals in the intestines of these mice did not efficiently absorb lipids. Taken together, these studies identify a Calcrl-Notch-Dll4 cascade that is essential for maintained lymphatic function in intestines.
We next challenged these lymphatic insufficiency mice with INDO to induce a mucosal injury leading to acute inflammation in order to examine their ability to resolve the inflammation. NSAIDs, like INDO, are known to inhibit both COX-1 and -2 enzymes and induce direct cytotoxic effects on the epithelium (43) . The dosage of INDO can be effortlessly regulated, does not effect survival, is clinically relevant, and provides a highly reproducible mouse model of intestinal injury (44) . Although INDO challenge is an established method to induce severe enteropathy in animals and recapitulates some aspects of human CD (increased mucosal permeability and inflammation), it is an acute inflammation model, which allows for full recovery, unlike chronic IBD models. When challenged with an INDO-induced mucosal injury, these Calcrl fl/fl /Prox1-CreER T2 mice exhibited persistent inflammation, which, unlike controls, did not fully resolve 7 days after injury, resulting in marked weight loss (Supplemental Figure 6 ). This is one of the first studies, to our knowledge, to evaluate the role of systemic lymphatic insufficiency on the progression and resolution of intestinal inflammation, and it underscores the critical importance of maintained lymphatic function for the proper response and resolution of acute intestinal inflammation. Additionally, it is important to note that most of the phenotype of persistent inflammation was observed in the ilea of TAM-and INDO-treated Calcrl fl/fl /Prox1-CreER T2 mice, which is in tune with the high expression of preproAM mRNA in the ileum compared with other parts of the small intestine (45) .
This study introduces a nonsurgical model of systemic lymphatic vascular insufficiency, currently lacking in the field (46) . Future studies with prolonged injury models, such as ischemia/reperfusion, irradiation, or dextran sodium sulfate-induced colitis, will be very informative. Furthermore, this model of lymphatic insufficiency can be used to explore the nature of paracellular versus transcellular lipid transport pathways, central/nervous system innervation of lymphatics to control lipid uptake, and the crosstalk between intestinal LECs and enterocytes in lipid transport. Although there are some inbred strains of dogs (Wheaten Terrier, Lundehund, Basenji, and Yorkshire Terrier) that develop spontaneous Figure 6A and Supplemental Figure 5B) . However, at the same time, DLL4 was downregulated in the lacteals, implying that lymphatic CLR expression is not directly responsible for the crypt upregulation of DLL4 and proliferation. Additionally, increased epithelial proliferation did not affect the reduced proliferation of LECs. The dysfunctional lymphatics in Calcrl fl/fl /Prox1-CreER T2 mice exacerbated inflammation, even though the crypts followed the expected pattern of proliferation, emphasizing the importance of lymphatic vessels in disease progression and tissue repair. Therefore, our study also provides insights into the molecular crosstalk between LECs of dysfunctional lacteals and the villus enterocytes upon inflammation.
AM signaling through CLR and its roles on lymphatic vessel proliferation and junctional organization potentially provide a pharmacologically tractable target to resolve inflammatory diseases. Since more than 50% of all clinically available drugs target GPCRs (47) , there is great interest in understanding pharmacological and biochemical properties of CLR and its associated RAMPs, with the ultimate goal of manipulating the GPCR/RAMP interface for treatment of human disease (48) . The elucidation of specific roles for CLR in intestinal lymphatic function may ultimately form the basis of GPCR-targeted approaches for the therapeutic treatment of lymphatic vascular diseases or the amelioration of inflammatory digestive conditions through modulation of lymphatic function.
In summary, our study strongly supports the importance of lymphatic CLR in intestinal disease progression and restoration, which is mediated, in part, through its effect on Notch signaling. The induction of the intestinal lymphatic AM signaling pathway may therefore aid in enhanced intestinal inflammation resolution, thus presenting a potential target in the treatment of IBDs. /J mice, which are also known as RiboTag mice, from The Jackson Laboratory (stock 011029). Cre-mediated recombination was induced by administering TAM (Sigma-Aldrich T5648) dissolved in corn oil and ethanol to mice aged 4-6 months for 5 consecutive days at a dose of 5 mg/40 g intraperitoneally, after which organs were harvested. These mice were tested for floxed, Cre, and excised alleles by genotyping after TAM administration. Primers used for genotyping the WT Calcrl allele were 5′-GCGGAGCATATTCAAT-CACAAG-3′ and 5′-GAAATGTGCTGTATGTTCAAGC-3′, for the Calcrl floxed allele were 5′-GCGGAG-CATATTCAATCACAAG-3′ and 5′-GACGAGTTCTTCTGAGGGGA-3′, for the Prox1-CreER T2 allele were 5′-CGAGCTCTTTCTCTCTACAGTTCAACA-3′ and 5′-GGCCAGTAACGTTAGGGAGAGG-3′, for the excised allele were 5′-GCGGAGCATATTCAATCACAAG-3′ and 5′-GAATAAGTTGAGCTGGG-CAG-3′, and for the Rpl22 tm1.1Psam allele were 5′-GGGAGGCTTGCTGGATATG-3′ and 5′-TTTCCAGACA-CAGGCTAAGTACAC-3′. Acute mucosal injury was induced by injecting INDO (Sigma-Aldrich I7378) dissolved in 5% sodium bicarbonate at 10 mg/kg body weight subcutaneously, following TAM injections, and then organs were harvested either 1 day after INDO (acute inflammation stage) or 7 days after INDO (recovery). A total of 61 male and female mice between 4 and 6 months of age were used in this study.
Methods

Animals
Cell culture. Human neonatal dermal LECs (HMVEC-dLyNeo-Der, Lonza CC-2812) were used within 8 passages and maintained on EGM-2MV bullet kit media (Lonza CC3202). For siRNA knockdown cells were seeded at 2 × 10 5 cells/well in 6-well plates and grown to 60%-80% confluency. Cells were transfected with either control siRNA (Santa Cruz Biotechnology sc-37007) or human CRLR siRNA (Santa Cruz Biotechnology sc-43705) at a concentration of 10 �M for 48 hours or were treated with either 10 nM human AM peptide (Bachem H-2932) in media or were treated with water (control) for 1 hour. For immunostaining, cells were plated in 2% gelatin-coated (Sigma-Aldrich G1393) sterile glass coverslips and grown to an 80% confluent monolayer before siRNA KD or AM treatment.
RNA and quantitative RT-PCR.
Lung and small intestinal tissue was collected in RNAlater (Ambion AM7021). RNA was extracted from whole tissue or cultured cells using TRIzol reagent (Ambion 15596026), followed by DNase (Promega M6101) treatment, and cDNA was prepared using iScript (Bio-Rad 170-8890 (49) . Briefly, tissue was placed in dissociation reagent 1 (PBS/30 mM EDTA/1.5 mMDTT) on ice for no longer than 15 minutes, followed by prewarmed dissociation reagent 2 (PBS/30 mM EDTA) with shaking to remove the submucosa and muscularis. The remaining sample was pelleted by centrifugation, and the cell pellets were used for harvesting HA-tagged RNA from Prox1-CreER T2 Serum component analysis measurements. Blood was collected from submandibular bleed, allowed to clot at room temperature for 1 hour, and separated using Microtainer tubes (BD 50089794). Serum albumin level was analyzed by the Animal Clinical Chemistry and Gene Expression Lab at University of North Carolina. Serum alanine aminotransferase and alkaline phosphatase levels were analyzed using VetScan comprehensive diagnostic profile rotor (Abaxis 500-7123).
Statistics. A total of 61 mice were used in this study. All experiments were performed 3 or more times, and data are represented as mean with SEM. Significance was either by determined by 2-tailed, type 2 Student's t test or 1-way ANOVA with Tukey's Multiple comparison test or 2-way ANOVA, with P values of less than 0.05 considered significant.
Study approval. All animal procedures were approved by the University of North Carolina Chapel Hill's Institutional Animal Care and Use Committee, and all attempts were made to minimize pain and distress.
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